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Synopsis
Maternal embryonic leucine zipper kinase (MELK), a serine/threonine protein kinase, has oncogenic properties and
is overexpressed in many cancer cells. The oncogenic function of MELK is attributed to its capacity to disable critical
cell-cycle checkpoints and reduce replication stress. Most functional studies have relied on the use of siRNA/shRNA-
mediated gene silencing. In the present study, we have explored the biological function of MELK using MELK-T1, a novel
and selective small-molecule inhibitor. Strikingly, MELK-T1 triggered a rapid and proteasome-dependent degradation
of the MELK protein. Treatment of MCF-7 (Michigan Cancer Foundation-7) breast adenocarcinoma cells with MELK-
T1 induced the accumulation of stalled replication forks and double-strand breaks that culminated in a replicative
senescence phenotype. This phenotype correlated with a rapid and long-lasting ataxia telangiectasia-mutated (ATM)
activation and phosphorylation of checkpoint kinase 2 (CHK2). Furthermore, MELK-T1 induced a strong phosphoryla-
tion of p53 (cellular tumour antigen p53), a prolonged up-regulation of p21 (cyclin-dependent kinase inhibitor 1) and
a down-regulation of FOXM1 (Forkhead Box M1) target genes. Our data indicate that MELK is a key stimulator of
proliferation by its ability to increase the threshold for DNA-damage tolerance (DDT). Thus, targeting MELK by the
inhibition of both its catalytic activity and its protein stability might sensitize tumours to DNA-damaging agents or
radiation therapy by lowering the DNA-damage threshold.
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INTRODUCTION
The preservation of genomic integrity is essential for cell ho-
moeostasis. Aberrant DNA structures can arise during an un-
perturbed S-phase [1]. If the DNA polymerase encounters an
anomalous DNA structure, it will stall. Prolonged stalling of rep-
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lication forks leads to fork collapse, formation of DNA double-
strand breaks (DSBs) and ultimately genome instability. How-
ever, DNA-damage tolerance (DDT) pathways have evolved to
allow replication through and beyond an altered template [2].
In addition, a well-co-ordinated network of signalling cascades,
termed the DNA-damage response (DDR), is activated. The DDR
senses DNA aberrations and transmits the damage signal to
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activate cell-cycle checkpoints in order to delay cell cycle pro-
gression and allow more time for repair. In the event of irrepar-
able DNA damage, the damaged cells will be eliminated from
the proliferative pool by either induction of senescence or cell
death [3].
Cancer cells show multiple abnormalities, including inherent
replication stress and DNA damage. They are able to survive
and proliferate because key checkpoints are weakened, thereby
increasing the barrier for activation of DDR signalling [4]. As a
result, cancer cells undergo cell division in an uncontrolled way.
Conventional chemotherapy seeks to kill cancer cells by causing
further DNA damage, which is sufficient to reach the increased
threshold for DDT. Alternatively, a therapeutic agent that could
reactivate a checkpoint has the potential to re-enable the cell
to detect and respond to DNA damage by senescence or cell
death.
Maternal embryonic leucine zipper kinase (MELK) belongs
to the sub-family of AMP-activated serine/threonine protein
kinases. It is the only member that does not require the liver
kinase B1 (LKB1) kinase for its activation [5]. Instead, it is
activated through autophosphorylation induced by a currently
unknown trigger [6] and potentially through phosphorylation by
cyclin-dependent kinases (CDKs) and mitogen-activated protein
(MAP) kinases [7]. MELK plays a major role in various cellular
and biological processes including neural progenitor cell renewal
[8], apoptosis [9,10], mRNA splicing [11], DNA repair [12] and
asymmetric cell division [13].
MELK has emerged as a potentially important target for can-
cer therapy. Indeed, MELK expression is dramatically increased
in cancers of various tissue origins with a high proliferation in-
dex, including glioblastomas that are known to be resistant to
chemo- and radiotherapy [14–16]. Moreover, a direct correla-
tion between high MELK expression and malignancy grade has
been reported in solid tumours like melanoma [17], breast cancer
[18], brain tumours [15,16] and, also recently, in haematolo-
gical malignancies like acute myeloid leukaemia (AML) [19].
The high expression level of MELK in undifferentiated can-
cer cells suggests a possible role for MELK in cancer stem-
cell maintenance and survival [16]. Tumour cells may derive
a proliferative advantage from the ability of MELK to inhibit
p53 (cellular tumour antigen p53) [20] and induce apoptosis
[9,10]. In addition, MELK has been implicated in DDR pathways
[12,21,22] and in the resistance of tumour cells to DNA-damaging
treatments [22]. Importantly, normal differentiated cells have a
very low expression level of MELK, offering the promise of a
manageable therapeutic window due to absent or low on-target
toxicity.
Previously, the novel quinolone-based compound OTSSP167
was reported to inhibit MELK kinase activity [23]. OTSSP167
was also shown to decrease solid-tumour growth from cancer
cell lines with high MELK levels, as deduced from xenograft as-
says. The demonstrated in vitro and in vivo efficacy and safety in
pre-clinical studies has led to the initiation of a clinical trial
phase-I program for OTSSP167. We have recently described
the tailor-made development of a potent (IC50 = 37 nM) and
cell-permeable small molecule inhibitor of the kinase domain of
Figure 1 Inhibition of MELK by MELK-T1
(A) Structures of MELK-T1 and Cpd2. (B) Dose-response curves of
MELK-T1 () and Cpd2 () for the inhibition of EGFP–MELK in an in vitro
kinase assay with SAMS peptide as substrate. The results from three
independent experiments were expressed as mean +− S.E.M. (C) Inhib-
ition of MELK autophosphorylation by MELK-T1. Dose-response curves
of MELK-T1 () and Cpd2 () were calculated by measuring the cor-
responding band intensities obtained by autoradiography (inset shows
representative autoradiogram and corresponding Coomassie stained
gel). Band intensity values were normalized against the corresponding
bands obtained from Coomassie stained gel. The results are expressed
as mean +− S.E.M. (n = 3).
MELK, coined MELK-T1 (Figure 1A) [24]. In the present study,
we show that MELK-T1 not only inhibits MELK but also trig-
gers its proteasome-mediated degradation. Moreover, we demon-
strate that MELK-T1 induces replication stress and activates the
immediate and delayed ataxia telangiectasia mutated (ATM)-
mediated DDRs that eventually lead to a replicative senescent
phenotype.
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EXPERIMENTAL
Cell culture and analysis
MCF-7 cells were cultured in high-glucose DMEM (Dulbecco’s
modified Eagle’s medium; LifeTechnologies), supplemented
with 10 % FBS (LifeTechnologies). Transfection of EGFP-
MELK and knockdown of MELK with siRNA were performed as
described previously [25]. A549 lung adenocarcinoma cells were
cultured in DMEM (Life Sciences) supplemented with 10 % FCS
(fetal calf serum; Thermo Scientific), 2 mM L-glutamine (Life
Sciences), 1 mM sodium pyruvate (Life Sciences) and 50 μg/ml
gentamicin (Life Sciences).
FACS analyses [25] and in vitro IC50 data profiling were car-
ried out as described [24]. IncuCyte-Growth curves based on
confluency measurements were constructed by imaging plates
using the IncuCyte system (Essen Instruments). BrdU (bromod-
eoxyuridine) incorporation assays and analysis of replication fork
dynamics were described previously [25]. In these experiments,
the compounds were added 2 h before fixing or harvesting the
cells. For EdU (5-ethynyl-2′-deoxyuridine) incorporation assays,
the Click-iT® Plus EdU Alexa Fluor® 488 Imaging kit (C10637)
of LifeTechnologies was used according to the manufacturer’s in-
structions. Images were scanned with the In Cell Analyzer 2000
(GE Healthcare Life Sciences), objective Nikon 10 × 0.45 and
the following filters: DAPI (exposure 25 ms) and FITC (expos-
ure: 200 ms).
For 3D-sandwich assays, MCF-7 cells were pre-treated with
the indicated compounds for 72 h in a 2D-setting before being
transferred to a BME (basement membrane extract)-gel matrix.
The pre-treated cells were embedded between two layers of Tre-
vigen Cultrex BME (Trevigen 3433-005-01) as follows. First, a
24-well plate was coated with ice-cold undiluted BME and in-
cubated for 1 h at 37 ◦C to solidify. Next, the cells were plated
on the first BME gel layer and incubated for 3–4 h to allow at-
tachment. After aspiration of the medium, the cells were covered
with ice-cold BME matrix, diluted with culture medium (BME
medium = 1:1). The plate was again incubated for 1 h to allow the
second BME layer to solidify. Finally, culture medium supple-
mented with the compound was added on top of the second BME
matrix. The assay plate was placed in a Cell-IQ imager (Chipman
Technologies), equipped with 5 % CO2 supply and images were
taken every 2 h for the next 10 days.
Antibodies
The following antibodies were used: Actin (Sigma), ATM (D2E2,
Cell Signaling Technologies), P-ATM (Ser1981, Abcam), CHK2
(checkpoint kinase 2; Cell Signaling Technologies), P-CHK2
(Thr68, Cell Signaling Technologies), MELK (Sigma), p21
(cyclin-dependent kinase inhibitor 1; Upstate), p53 (PAB 1801,
Santa Cruz), p53 DO-1 (Santa Cruz), P-p53 (Ser15, Cell Signal-
ing Technologies) and Vimentin (Santa Cruz).
BrdU and γ H2A.X (phospho-histone H2AX) immunostain-
ings were performed following a treatment for 2 h with the in-
dicated compounds. Cells were fixed in 10 % formalin solution
(Sigma–Aldrich) for 10 min at room temperature and 20 min
in ice-cold methanol, after which they were washed 3× in
PBS. Subsequently, the cells were blocked for 1 h in PBSAT
(PBS + 1 % BSA + 0.1 % Tween) and incubated overnight
with the primary antibody in PBSAT. The cells were washed 3×
with PBSAT and incubated with the secondary antibody for 1 h at
room temperature, again washed 3× with PBSAT and incubated
with the Hoechst staining solution (1/2000 in PBSAT).
In vitro kinase assays
MCF-7 cells were transiently transfected with EGFP–MELK
and lysed after 48 h, as previously described [6]. EGFP–MELK
was immunoprecipitated using GFP-trap beads (Chromotek).
The bead suspension was used in an in vitro kinase assay with
the indicated concentrations of the compounds for autophos-
phorylation of MELK or with SAMS (substrate peptide for 5′-
adenosine monophosphate-activated protein kinases (AMPKs)
peptide. Autophosphorylation of MELK was analysed by auto-
radiography after SDS/PAGE. The IC50 values were calculated
from the dose-response curves via non-linear regression curve fit
in GraphPad Prism.
Microarrays
MCF-7 cells were treated with 10 μM MELK-T1 for 48 h. Cells
were lysed using RLT (RNeasy lysis) buffer (Qiagen) and RNA
was extracted with the RNeasy 96 kit (Qiagen). All microarray-
related steps for target preparation, including the amplification
of total RNA and labelling, were carried out as described in the
GeneChip®3′ IVT Express Kit User Manual (Affymetrix 2004).
Biotin-labelled target samples were hybridized to GeneChip®
Human Genome HT U133 PLUS PM 96-Array containing probes
for approximately 19000 genes. Target hybridization was pro-
cessed on the GeneTitan® Instrument according to the instruc-
tions provided in the User Guide for Expression Array Plates.
Images were analysed using the GeneChip® Command Console
Software (AGCC; Affymetrix). All data were processed using
the statistical computing R-program (R version 3.0.1; R Devel-
opment Core Team) and Bioconductor tools [26]. The gene ex-
pression values were computed using RMA (robust multi-array
average) [27]. Grouping of the individual probes into gene-
specific probe sets was performed based on Entrez Gene using
the metadata package hthgu133pluspmhsentrezg (version 15.1.0
[28]). The resulting log2-transformed data were the basis for
differential expression analysis using Significance Analysis of
Microarrays software [29]. The affected pathways were ana-
lysed using MLP (mean log P analysis) [30] and IPA (Ingenu-
ity Pathway Analysis; Ingenuity Systems, www.ingenuity.com).
The data have been submitted in GEO (gene expression omnibus)
(GSE62477).
Statistics
The results are presented as means +− S.E.M. for at least three in-
dependent experiments. Statistical significance between the con-
trol and the experimental groups was tested using Student’s t test.
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RESULTS
Inhibitory potency of MELK-T1
As described previously [24], the transamide carbonyl oxygen of
MELK-T1 (Figure 1A) binds to the backbone NH of Cys89 in the
hinge region of the catalytic domain of MELK. In addition, the
N-phenyl benzamide core is kept in a planar conformation by an
intramolecular hydrogen bond between the ortho-methoxy and
the amide-NH groups. We synthesized an analogue of MELK-
T1 named Compound 2 (Cpd2) (Janssen R&D; Figure 1A), in
which the methylation of the amide disturbs the planarity of
the N-phenyl benzamide and probably also the binding to the
hinge region. Accordingly, this compound showed no detectable
inhibition of MELK activity in vitro (IC50 > 10 μM) and was
used as a negative control. To characterize the potency of MELK-
T1 against full-length MELK protein, exogenously expressed
EGFP–MELK was immunoprecipitated from MCF-7 cells. Next,
its activity was measured using the SAMS peptide as substrate
in the presence of the indicated concentrations of the compounds
(Figure 1B). An IC50 of 0.2 μM was determined for MELK-T1,
but no inhibitory activity could be detected for Cpd2. Similar
data were obtained when the kinase activity was derived from the
autophosphorylation of MELK (IC50 = 0.52 μM) (Figure 1C).
These IC50 values for full-length MELK were 5–14-fold higher
than previously reported for the catalytic domain (residues 1–
340) of MELK [24], indicating that the C-terminal regulatory
domain and/or interacting proteins somehow decrease the affinity
for MELK-T1.
MELK-T1 triggers the degradation of endogenous
MELK
To compare the effects of MELK-T1 and Cpd2 on cultured MCF7
cells, we used the compounds at a final concentration of 10 μM.
The required concentration was higher than that needed to inhibit
purified MELK (Figure 1), hinting at a limited permeability or
stability of MELK-T1 in MCF7 cells. It was also higher than
the concentration (1.5 μM) previously used for Ba/F3 cells [24],
indicating that the sensitivity to MELK-T1 is cell-type dependent.
Exposure of unsynchronized MCF-7 cells (Figure 2A) to
MELK-T1 triggered a fast reduction in the endogenous MELK
protein level within 4 h of compound addition. The MELK pro-
tein level is known to be strictly controlled [31,32]. Indeed, the
kinase is expressed in proliferating cells, but is undetectable in
differentiated cells. Also, the MELK-encoding gene is an E2F
(transcription factor E2F1) target and is induced during S-phase
[31]. The protein level reaches a maximum during the G2/M-
phase of the cell cycle and drops again at the mitotic exit [31].
The fast reduction in endogenous MELK protein after the ad-
dition of MELK-T1, irrespective of the cell-cycle phase, hints
at a direct effect of the compound on protein stability rather
than an effect through interference with cell-cycle progression.
Moreover, a similarly fast loss of MELK protein was detected in
the A549 lung adenocarcinoma cell line, excluding a cell-line-
specific effect (Supplementary Figure S1).
Figure 2 MELK-T1 triggers the proteasome-mediated degradation
of MELK protein
(A) Immunoblot analysis of MELK and actin levels in lysates of com-
pound-treated MCF-7 cells for the indicated times. (B) Immunoblot of
MELK and actin levels in lysates of MCF-7 cells that were pre-treated
with 2 μM of the proteasome inhibitor MG132 for 1 h before addition of
the indicated compound for 6 h. The blots are representative for three
experiments.
To further explore the MELK-T1-induced down-regulation of
MELK, MCF-7 cells were pre-treated with the proteasome inhib-
itor MG132 for 1 h prior to the addition of MELK-T1. Interest-
ingly, adding MG132 abolished the MELK-T1-induced reduction
in cellular MELK protein (Figure 2B), indicating an active and
controlled degradation mechanism by the proteasome.
Inhibition/degradation of MELK causes an S-phase
arrest
FACS of cell-cycle distribution of synchronized MELK-T1-
treated MCF7 cells revealed a significant reduction in the per-
centage of S-phase cells, with a corresponding increase in the
G1 cell population (Figure 3A). This observation is in agreement
with our previous work showing a delay in S-phase progression
after a MELK knockdown in U87 glioblastoma cells [25]. Next,
MCF7 cells were grown in the presence of EdU, a nucleoside
analogue of thymidine that is incorporated into DNA during rep-
lication. In accordance with the FACS data, the relative number
of EdU-positive cells was decreased after the inhibition of MELK
(Figure 3B), consistent with the notion that MELK plays a crucial
role in S-phase.
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Figure 3 MELK-T1 induces a delay in the progression of MCF-7 cells through S-phase
(A) Time-line showing the treatments and the incubation periods used for MCF-7 cell cultures. The histograms show the
cell-phase distribution of MCF-7 cells that were treated as explained in the time-line. Results are expressed as percentage
changes (mean +− S.E.M.; n = 3), *P< 0.05. (B) Representative immunohistochemistry images of MCF-7 cells treated
with the indicated compounds for 96 h showing EdU incorporation (green) and Hoechst staining (blue). The percentage of
positively stained EdU cells was normalized to the percentage of positively stained EdU cells of the DMSO control condition
(0 μM). The results are expressed as mean +− S.D. (n = 3), **P< 0.01.
The down-regulation of MELK induces stalled
replication forks and DSBs
To exclude general DNA-damaging properties of MELK-T1, we
performed both DNA mobility shift studies (Figure 4A) and DNA
intercalation studies (Figure 4B). At concentrations up to 50–
100 μM MELK-T1 did not show direct DNA damaging proper-
ties in these in vitro assays.
Next, we explored whether the down-regulation of protein
caused replication stress in MCF-7 cells. Both the siRNA-
mediated knockdown of MELK and a short-term treatment with
MELK-T1 (2 h) resulted in an increase in DSBs in MCF-7 cells
synchronized in S-phase (Figures 4C–4E), as visualized by the ac-
cumulation of γ H2A.X foci. The down-regulation of MELK also
caused a clear increase in the number of cells with γ H2A.X foci
in asynchronized cells, but had no such effect in cells that were
arrested by serum starvation in G0 (Supplementary Figure S2). In
these experiments, the simultaneous staining for BrdU incorpor-
ation confirmed that the increased accumulation of γ H2A.X was
only detected in cells undergoing DNA replication. Collectively,
these data clearly show that the induction of DSBs is S-phase
specific.
Subsequently, the replication in MCF-7 cells was monitored
by the successive labelling of newly synthesized DNA with the
thymidine analogues iododeoxyuridine (IdU) and chlorodeoxy-
uridine (CldU). This allows the measurement of fork progression
and the quantification of stalled forks [25]. Inhibition or knock-
down of MELK resulted in a 35 % decrease in the average length
of fibres labelled with CldU, reflecting an average decreased fork
progression speed (Figure 4F). A representation of the distribu-
tion of frequency of fork velocities (Figure 4G) showed that both
inhibition and knockdown of MELK caused a shift, with a re-
duced number of fast-progressing forks and an increased number
of slowly-progressing forks. Moreover, the inhibition or knock-
down of MELK was associated with an increased number of
asymmetrical forks, pointing to a higher frequency (∼40 %) of
stalled forks (Figure 4H). This observation cannot be explained
by mechanically-broken DNA fibres, because only forks with
the two halogenated labels were considered for the quantitative
assays. In conclusion, both the inhibition and the depletion of
MELK induced replication stress during an unperturbed S-phase
in MCF-7 cells.
MELK-T1 activates the ATM-mediated DDR
The siRNA-mediated knockdown of MELK leads to activation
of the ATM–CHK2 pathway [25]. ATM-mediated downstream
signalling in response to DSBs can be divided into two major
cascades [33]. During the rapid response, activated ATM phos-
phorylates and activates the effector kinase CHK2. Activated
CHK2 in turn phosphorylates CDC25A (dual specificity phos-
phatase Cdc25A) and targets it for ubiquitination and degrad-
ation. The depletion of CDC25A leads to an accumulation of
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Figure 4 Effects of MELK-T1 on DNA structure and replication
(A) The agarose gel shows a DNA-mobility shift assay performed with the indicated concentrations of MELK-T1.
(B) An in vitro DNA intercalation assay was performed taking doxorubicin, a known DNA intercalator, as a positive control.
Fluorescence measurements of an ethidium bromide competition assay were performed with a concentration range of
MELK-T1 and doxorubicin. The results (percentage of DMSO control) are expressed as mean +− S.D. (n = 3). (C) Schematic
of the procedure used to synchronize MCF-7 cells in S-phase. The cells were incubated with BrdU (30 μg/ml) for 45 min
before fixation. O/N, overnight. Representative images from confocal microscopy showing γ H2A.X, BrdU and DAPI staining
in cells treated as illustrated in the time-line. (D) Quantification of the number of γ H2A.X positive cells (percentage of total).
At least 300 cells were counted in each condition. Cells with five or more foci were considered γ H2A.X positive. The results
are expressed as mean +− S.E.M. (n = 3). *P< 0.05. (E) Comparison of the average γ H2A.X raw signal intensity from at
least 500 cells for the indicated conditions. The results from three independent experiments were expressed as mean
+− S.E.M. *P< 0.05. (F) Fork-progression rate was quantified as described previously [25] under the indicated conditions
and expressed as kb/min. At least 500 fibres were counted from each condition in three independent experiments. The
results are expressed as mean +− S.E.M. **P< 0.001. (G) Distribution of the fork rates among the fibre populations in
the indicated conditions. The results are expressed as mean +− S.E.M. (n = 3). (H) Quantification of stalled forks (ratio
of stalled forks/number of ongoing forks × 100). At least 70 replication units were counted for each condition in three
independent experiments. The results are expressed as mean +− S.E.M. *P< 0.05.
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phosphorylated CDK2–cyclin complexes and therefore a cell-
cycle arrest. The delayed response transforms this cell-cycle ar-
rest into a long-term arrest by consecutive activation of ATM and
p53, leading to an increased expression of the CDK inhibitor p21.
Both ATM-mediated cascades were monitored in a time-
course analysis of MELK-T1-treated MCF-7 cells. ATM and
CHK2 were already activated 20 min after the addition of MELK-
T1, whereas the sustained p53 activation and p21 up-regulation
appeared later (Figures 5A and 5B). Importantly, MELK-T1
triggered the same signalling cascade in a lung-adenocarcinoma
cell line A549, indicating that this response is not limited to
MCF-7 cells (Supplementary Figures S3A and S3B). Overall,
our results indicate that the inhibition and degradation of MELK
protein induces both the early and the delayed ATM-mediated
DDR response, leading to the induction of a cell-cycle arrest.
Transcriptional effects of MELK-T1
To explore whether the effect of MELK inhibition on the ATM-
mediated DDR also leads to downstream transcriptional effects,
we carried out a gene expression profiling study. A 48-h treatment
of MCF-7 cells with 10 μM MELK-T1 resulted in the down-
regulation of 648 genes and up-regulation of 607 genes, with a
 1.5-fold change in the transcript level (Supplementary Table
S1). IPA revealed that DDR, cell-cycle control of chromosomal
replication and ATM signalling were among the most affected
pathways (Figure 6A). Approximately 30 % of the genes annot-
ated to these pathways were affected, mostly down-regulated,
after a treatment with MELK-T1 (Figures 6A and 6B). These
data independently confirm that the down-regulation of MELK
leads to a global ATM-mediated DDR response.
Intriguingly, we also noticed a 2.6-fold down-regulation of
FOXM1, an oncogenic transcription factor that forms a complex
with MELK and is dependent on phosphorylation by MELK
for its activity in glioma stem cells [34]. Recently, Alachkar
et al. [19] also noticed a down-regulation of FOXM1 and its
downstream target genes upon treatment of AML cell lines with
OTSSP167 [19]. Our microrarray gene MELK target list con-
tained 20 FOXM1 target genes and 18 of these were down-
regulated (Supplementary Table S2). These included protein
kinases PLK1 (Polo-like kinase 1) and PLK4 (Polo-like kinase
4) and explain why we found the mitotic roles of polo-like kinase
among the top canonical pathways analysis (Figure 6A). Strik-
ingly, we found that the MELK transcript itself was also signi-
ficantly down-regulated (2.21-fold). This agrees with the recent
report that MELK itself is a FOXM1 target [35].
A prolonged treatment with MELK-T1 causes
growth inhibition and senescence
As expected from the induction of the DDR response and
subsequent induction of p21, a prolonged treatment of MCF-7
cells with MELK-T1 caused a stagnant growth at 30 %–40 %
confluency (Figure 7A), as confirmed by a lower number of cells
(Figure 7B). Also, this growth arrest was accompanied by an
enlarged and flattened cell morphology, which are typical features
Figure 5 MELK inhibition induces an early and delayed ATM-
mediated DDR response
Immunoblot analysis with the indicated antibodies of lysates from com-
pound-treated MCF-7 cells for a short period (A) or a long period (B).
P-ATM = ATM phosphorylated on Ser1981, P-CHK2 = CHK2 phos-
phorylated on Thr68, P-p53 = p53 phosphorylated on Ser15. The blots
are representative for three experiments.
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Figure 6 MELK function modulates the expression of genes involved in DNA-damage signalling
(A) Table representing IPA analysis results of the top canonical pathways affected 48 h after MELK-T1 treatment. ‘Overlap’
demonstrates the percentage of differentially expressed genes in each pathway. (B) Heat-map representation of the
significant differentially expressed genes in the top canonical pathways as shown in (A).
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of senescent cells under 2D-growth conditions (Figures 7A and
7B). MCF-7 cells form distinctive and highly migrating spher-
oids under specific 3D-sandwich assay conditions. Remarkably,
MELK-T1 pre-treated cells lost this characteristic spheroid
morphology as well as the capacity to migrate and proliferate
(Figure 7C; Supplementary Movies S1–S3), indicating that
MELK-T1 seriously reduces cell growth of MCF-7 cells.
To explore whether the inhibitory effect of MELK-T1 on cell
growth is dependent on the genetic background, MELK-T1 was
probed against a panel of 81 solid tumour cancer cell lines ( c©
Oncolead GmbH & Co. KG). Statistical analysis was performed
using proprietary software developed at Oncolead. In 46 of these
81 cell lines, a GI50, i.e. the concentration producing 50 % of
maximal inhibition of cell proliferation, was reached at a concen-
tration below 20 μM after 96 h of incubation. A representation
of the Z-scores is shown in Figure 8. The inhibition of growth by
MELK-T1 was not correlated with the genetic background, im-
plying that no molecular biomarker profile could be determined.
These data clearly show that MELK has a role in a general onco-
genic pathway not linked to a particular cancer type or mutation
profile.
DISCUSSION
So far, only a limited number of MELK inhibitors have been de-
scribed [36]. These inhibitors are clearly inhibitory to cancer-cell
growth, both in vitro and in xenograft mouse models, although the
underlying molecular mechanism is poorly understood. There-
fore, the need for a thorough cellular validation of MELK in-
hibitors remains high. In the present study, we have applied our
recently described inhibitor MELK-T1 to further unravel the bio-
logical function of MELK [24].
We observed that MELK-T1 initiates a rapid down-regulation
of endogenous MELK by triggering its proteasome-dependent
degradation. This effect on MELK protein stability has not been
described for any other MELK inhibitor. Since MELK-T1 is
a type I, ATP-mimetic inhibitor [24], its binding to MELK pos-
sibly stabilizes the ATP-bound conformation, which could trigger
the degradation of MELK protein by either of two mechanisms.
Firstly, MELK is a known Hsp90 (heat shock protein 90) client
[37]. Protein kinase clients are recruited to the Hsp90 molecu-
lar chaperone system via Cdc37 (Hsp90 co-chaperone Cdc37),
which simultaneously binds Hsp90 and a kinase and regulates
the Hsp90 chaperone cycle. However, ATP-competitive inhibit-
ors such as MELK-T1 can deprive the kinases of access to the
Hsp90–Cdc37 chaperone system, leading to their degradation
[38]. Secondly, acquisition of the fully active conformation of
MELK, capable of ATP-binding and substrate binding, is con-
trolled at multiple layers. MELK activity is dependent on redu-
cing agents, owing to an intramolecular disulfide bond that leads
to structural distortions [39] and also on an autophosphorylation
event at Thr167 [6]. Moreover, the ubiquitin-associated domain
(UBA) located next to the kinase domain of MELK contrib-
utes to protein folding and proper conformation of the kinase
domain [39]. UBA domains bind to ubiquitin and contribute to
all ubiquitin-dependent cellular processes, including proteasome-
mediated degradation. A nucleotide-dependent communication
between sub-domains can therefore be postulated which could
reduce the half-life of the activated (ATP-bound) conformation
of the MELK protein. A high affinity ATP-mimetic inhibitor,
such as MELK-T1, might stabilize the active conformation and
in this way trigger active degradation via ubiquitination.
We have previously shown that a lack of MELK, caused by its
siRNA-mediated knockdown in U87 cells, results in a prolifer-
ation arrest [25]. A similar phenotype was observed in MELK-
T1-treated MCF-7 cells (present work). In addition, we observed
a MELK-T1 induced down-regulation of FOXM1 and a corres-
ponding decreased expression of its target genes. This agrees with
earlier described effects of the MELK inhibitor OTSSP167 in
AML cell lines [23]. A prolonged treatment of MCF-7 cells
with MELK-T1 also inhibited MELK transcription, most prob-
ably via down-regulation of FOXM1. The lower MELK tran-
script level combined with an increased MELK protein degrada-
tion results in an almost complete elimination of MELK protein
which, moreover, potentially induces a feedback loop through
a further reduction and inactivation of FOXM1. This long-term
shutdown of both MELK and FOXM1 may be a requirement for
the observed irreversible senescence phenotype after prolonged
incubation with MELK-T1.
Exploring the mechanism of action of MELK-T1 that leads to
the observed proliferation arrest, we demonstrated that inhibition
and active degradation of MELK protein in MCF-7 and A549
cells activate an ATM-mediated DDR. In particular, MELK in-
hibition/depletion leads to the consecutive phosphorylation of
ATM, CHK2, p53 and the up-regulation of p21, as well as an ac-
cumulation of γ H2A.X foci in S-phase. Moreover, an increased
incidence of stalled replication forks and a prolonged S-phase
were observed. Our finding that the knockdown of MELK and
the addition of MELK-T1 caused the same type of replication
stress is strong evidence that MELK-T1 acts through inhibition
of MELK. In this respect, it is also worthy of note that Cpd2, des-
pite its very similar structure, had no such effects. Nevertheless,
as is true for any drug, it is difficult to entirely rule out off target
effects of MELK-T1.
Normal cells have a low expression level of MELK and effect-
ive checkpoints which ensure a balanced equilibrium between
DDR and senescence or apoptosis in the event of unrepairable
DNA (Figure 9A). In cancer cells, however, MELK is often
overexpressed. An increased MELK function may be crucial to
overcome DNA-damage checkpoint activation upon replication
stress and thereby avoid senescence or apoptosis (Figure 9B).
Moreover, higher MELK levels can contribute to an increased
resistance to DNA-damage inducing chemotherapeutics or ra-
diation therapy. Inhibition and depletion of MELK protein by
MELK-T1 treatment may re-enable cancer cells to detect and
respond to DNA damage (Figure 9C).
Importantly, an inhibitor-induced degradation of MELK has
not been described for any other MELK inhibitor. MELK-T1
could therefore display a different mode of action. Drugs that
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Figure 7 MELK-T1 induces a growth arrest and a senescent phenotype
(A) Representative phase-contrast images obtained by live content imaging of compound-treated MCF-7 cells over a time
course of 140 h and growth curves based on confluency measurements of the phase-contrast images. (B) Representative
immunohistochemistry images of compound-treated MCF-7 cells for 96 h showing vimentin (green) and Hoechst staining
(blue). The left graph shows the number of cells based on nuclear count of the obtained immunohistochemistry images and
normalized to the DMSO control (0 μM). In the right graph, the average cytoplasmic area was quantified and normalized to
the DMSO control (0 μM). The results are expressed as mean +− S.D. (n = 3). (C) Representative phase-contrast images
of a sandwich assay of compound-pre-treated MCF-7 cells followed over a time period of 8 days.
induce protein degradation are likely to have different pharma-
cological effects from those that simply obstruct a binding site,
as kinase-independent signalling will also be eliminated. The up-
regulation of MELK in cancers is due to an increased protein
level and not to gain-of-function mutations, as is seen for sev-
eral other oncogenic kinases [40]. Importantly, both increased
MELK activity and protein level contribute to cancer-cell prolif-
eration [36]. Accordingly, we noted that the effects of a knock-
down of MELK in glioblastoma cells could be partially rescued
with a catalytic-death mutant of MELK [25], hinting at kinase-
independent functions of MELK in cell proliferation.
In the present manuscript, we mainly focused on the MCF-
7 breast adenocarcinoma cell line. The effective treatment of
breast cancer remains a major challenge, owing to the recurrence
of treatment-resistant tumours. This includes the use of platinum-
based chemotherapy, which fails because tumours acquire toler-
ance to drug-induced DNA damage. Targeting MELK function by
MELK-T1 might therefore sensitize tumours to DNA-damaging
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Figure 8 MELK-T1 shows a broad activity range in the Oncolead cell-line panel
Z-scores of the incubation with MELK-T1 for 96 h are represented for the indicated cell lines (left) and their tissue origin
(right).
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Figure 9 Model of how MELK increases the DDT barrier
(A) Normal differentiated cells have a low expression level of MELK. In the event of DNA damage, the ATM-mediated DDR is
switched on to maintain cell homoeostasis by a balanced equilibrium between repair, in the case of manageable damage
and proliferation arrest or cell death, in the case of irreparable DNA damage. (B) In cancer cells MELK is overexpressed
and keeps the ATM-mediated DDR in check, rendering the cell unable to respond. This co-incides with an accumulation
of stalled replication forks, formation of DSBs and therefore genetic instability. (C) Inhibition and degradation of MELK by
MELK-T1 in cancer cells lowers the threshold for DDT and reactivates/enhances the DDR. This sensitizes cancer cells to
their inherent DNA damage and replication stress and results in growth arrest and senescence.
agents or radiation therapy by lowering the threshold for DDT.
Alternatively, MELK inhibitors as a single-agent therapy could
be appropriate for cancers suffering to a sufficiently high extent
from inherent replication stress. On the other hand, the growth in-
hibitory effects of MELK-T1 on a broad panel of cancer cell lines
indicate that MELK is an interesting therapeutic target for several
cancers and that MELK-T1 is a very promising lead compound
due to its combined effect on MELK activity and stability.
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